Home/Ochre Bio/Sarah Batey
SB

Sarah Batey

Chief Operating Officer

Ochre Bio

Ochre Bio Pipeline

DrugIndicationPhase
OB-220Significant FibrosisPreclinical
Undisclosed Metabolic ProgramCirrhosis (F4 MASH)Preclinical
Undisclosed Multiple Mechanism ProgramSignificant FibrosisDiscovery
Undisclosed Regeneration ProgramCirrhosisDiscovery